Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

CryoLife achieves first implant of a combination aortic-mitral allograft heart valve

CryoLife : 14 May, 2008  (Company News)
CryoLife has completed the first implantation of the combination aortic-mitral allograft heart valve in a patient at the Cleveland Clinic.
The surgery was performed by Dr Jose Navia, a cardiac surgeon with the Heart and Vascular Institute at the Cleveland Clinic.

The method used to process the combination aortic-mitral human heart valve was developed by CryoLife in collaboration with the Cleveland Clinic. The innovative valve was developed as a replacement option for patients with infective endocarditis involving both the aortic and mitral valves. Infective endocarditis is a condition in which the structures of the heart, particularly the heart valves, are infected.

'Infections involving both the mitral and aortic valves put patients at very high risk for serious complications that can result in death,' said Dr Navia. 'With the new human tissue combination aortic-mitral heart valve, we are hoping to provide an infection-resistant treatment option to offer patients.'

Dr Navia developed the concept for the aortic and mitral valve replacement option and is a paid consultant for CryoLife.

'It was very exciting to work closely with the Cleveland Clinic on this breakthrough development in cardiac reconstruction procedures,' said Steven G Anderson, president and chief executive officer of CryoLife. 'At CryoLife, we are dedicated to advancing technology for the treatment of patients suffering from complex cardiac disease. The new aortic-mitral allograft heart valve is a wonderful new option for patients suffering from infective endocarditis.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo